Repligen Corporation (RGEN)

159.27 -2.60 (-1.61%) At close: 04:00PM EST

Repligen Corporation

Building 1
Suite 100 41 Seyon Street
Waltham, MA 02453
United States
781 250 0111
https://www.repligen.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full-time employees: 2,025

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Anthony J. Hunt	CEO & Director	1.59M	9.43M	1964
Mr. James R. Bylund	Chief Operating Officer	820.26k	292.13k	1964
Ms. Christine Gebski	Senior Vice President of Filtration & Chromatography	625.76k	N/A	1969
Mr. Ralf Kuriyel	Senior Vice President of Research & Development	661.75k	814.23k	1959
Mr. Olivier Loeillot	President & Chief Commercial Officer	N/A	N/A	N/A
Mr. Jason K. Garland	Chief Financial Officer	N/A	N/A	1974
Mr. Keith Lee Robinson	Chief Information Officer	N/A	N/A	N/A
Ms. Sondra S. Newman	Global Head of Investor Relations	N/A	N/A	N/A
Ms. Kimberly A. Cornwell	General Counsel	N/A	N/A	N/A
Dr. Jaime M. Humara Ph.D.	Senior Vice President of Marketing	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Corporate governance

Repligen Corporation’s ISS governance QualityScore as of 1 December 2023 is 2. The pillar scores are Audit: 5; Board: 3; Shareholder rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.